COMMUNIQUÉS West-GlobeNewswire

Cara Therapeutics Announces No Modifications in Trial Size for Phase 2 Trial of Oral KORSUVA™ in Chronic Kidney Disease Patients with Pruritus after Completion of Interim Statistical Assessment
22/07/2019
- Study now fully enrolled; topline data expected in 4Q 2019 - STAMFORD, Conn., July 22, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and [...]
Achillion’s ACH-5228 Achieves Positive Results in Phase 1 Multiple Ascending Dose Study in Healthy Volunteers
22/07/2019
ACH-5228 delivers near complete and sustained inhibition of the complement alternative pathway Twice-daily oral administration to move forward in Phase 2 trials Investigational New Drug (IND) application to be submitted [...]
HEXO’s dried flower and award-winning Elixir spray now available in Alberta
22/07/2019
GATINEAU, Quebec, July 22, 2019 (GLOBE NEWSWIRE) -- HEXO Corp (“HEXO” or the “Company”) (TSX: HEXO; NYSE: HEXO) cannabis products are now available to Alberta consumers for the first time after finalizing an agreement [...]
Les fleurs séchées et le spray primé Elixir de HEXO maintenant disponibles en Alberta
22/07/2019
GATINEAU, Québec, 22 juill. 2019 (GLOBE NEWSWIRE) -- Pour la première fois, les produits de cannabis de HEXO Corp (« HEXO » ou la « Société ») (TSX : HEXO; NYSE : HEXO) sont disponibles pour les consommateurs de l' [...]
Novo Nordisk A/S – Share repurchase programme
22/07/2019
Bagsværd, Denmark, 22 July 2019 – On 7 May 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
Transactions under Novozymes’ stock buyback program
22/07/2019
Please read the full announcement in the attached PDF Attachment 2019_24_Stock_Buybackprogram_EN
Adynxx Adds Gregory J. Flesher to Board of Directors, Completes Up-listing to OTCQB Market
22/07/2019
SAN FRANCISCO, July 22, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and first-in-class therapeutics [...]
Orion Corporation: Managers’ transactions – Timo Lappalainen
22/07/2019
ORION CORPORATION MANAGERS’ TRANSACTIONS 22 July 2019 at 10.45 EETS Orion Corporation: Managers’ transactions – Timo Lappalainen Orion Corporation has received the following disclosure under Market Abuse Regulation (EU [...]
Aino Health AB (publ): Aino Health Germany signs partnership agreement with 55BirchStreet
22/07/2019
Aino Health and 55BirchStreet, a German digital consulting company, have signed a partnership agreement. 55BirchStreet will sell licenses and implementation services for Aino’s health management platform HealthManager [...]
Saniona selects highly promising preclinical candidate with broad potential in autoimmune disorders
22/07/2019
PRESS RELEASE July 22, 2019 Preclinical candidate SAN903 to be developed to Phase 1 clinical study in 18 months First-in-class compound with a new mode-of-action and strong IP Saniona AB (OMX: SANION) today announces [...]
PCI Biotech: Extension of preclinical research collaboration agreement with a top-10 large pharma company
22/07/2019
Oslo (Norway), 22 July 2019 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma company [...]
Sandoz announces first patient enrolled in clinical study for proposed biosimilar denosumab in osteoporosis
22/07/2019
Integrated Phase I/lll study for proposed biosimilar denosumab to confirm matching efficacy, safety and immunogenicity with reference medicine[1] Osteoporosis accounts for 8.9m bone fractures annually, including [...]
The WHO Recognizes NOX Inhibitors as New Therapeutic Class and Approves Setanaxib for GKT831
22/07/2019
World Health Organization (WHO) recognized GKT831 as first representative of NOX inhibitor therapeutic class The recommended new stem “naxib” recognizes NOX inhibitors as a new therapeutic class The NOX inhibitor [...]
L'OMS enterine les inhibiteurs des NOX en tant que nouvelle classe thérapeutique et approuve Setanaxib pour le GKT831
22/07/2019
L'Organisation Mondiale de la Santé (OMS) reconnaît le GKT831 en tant que premier représentant de la classe thérapeutique des inhibiteurs des NOX Le nouveau segment commun « naxib » approuvé par l’OMS entérine les [...]
Philips delivers Q2 sales of EUR 4.7 billion, with 6% comparable sales growth and 8% comparable order intake growth; income from continuing operations increases to EUR 260 million and Adjusted EBITA margin improves to 11.8%
22/07/2019
July 22, 2019 Second-quarter highlights • Sales in the quarter amounted to EUR 4.7 billion, with 6% comparable sales growth • Comparable order intake increased 8% • Income from continuing operations increased to EUR 260 [...]
Roche expands the Global Access Program beyond HIV to also include diagnostic tests for Tuberculosis, Hepatitis, and Human Papillomavirus
22/07/2019
Access to innovative diagnostic solutions will contribute to the World Health Organization’s infectious disease elimination goals Improving access to reliable diagnostics for disease management in countries with the [...]
Roche étend le Global Access Program à des maladies autres que le VIH, incluant désormais aussi des tests diagnostiques pour la tuberculose, l’hépatite et le papillomavirus humain
22/07/2019
L’accès à des solutions diagnostiques novatrices contribuera aux objectifs d’élimination des maladies infectieuses de l’OMS Amélioration de l’accès à des diagnostics fiables pour la prise en charge des maladies dans les [...]
Orphazyme to prepare for filing of arimoclomol in US for Niemann-Pick disease Type C (NPC)
21/07/2019
Orphazyme A/S Company announcement No. 18/2019 Company Registration No. 32266355 US Food and Drug Administration (FDA) agrees to Orphazyme’s plan to file New Drug Application (NDA) in US On track to file NDA and [...]
Oncology Venture – First day of trading in investor warrants
21/07/2019
Press release Hørsholm, Denmark and Cambridge, MA, US, July 21, 2019 – Oncology Venture A/S today announces that investor warrants will be traded on Nasdaq First North starting on July 24, 2019, under the short name OV [...]

Pages